Plasma cell myeloma
RecruitingStudy comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients
Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients
- Disease:Plasma cell myeloma
- Substances:DaratumumabDexamethasone+2
Denmark- Participants:18–64 years · 65+ years
- Substances:Daratumumab
- Sponsor:Emn Trial Office S.r.l. Impresa Sociale















